Here’s what you should know.
1. Boston Scientific closed the transaction on Nov. 22, 2016.
2. Boston Scientific will fold in EndoChoice’s portfolio into its product line.
3. Boston Scientific said it would evaluate its “strategic options” for the Full Spectrum Endoscopy colonoscope. It’ll announce any plans it has for the device by the year’s end.
4. Boston Scientific isn’t projecting this deal to affect its earnings this year, and it expects profitability in the following years.
More articles on gastroenterology/endoscopy:
Outreach to cirrhosis patients increases likelihood of liver cancer screening: 3 study insights
GI leader to know: Dr. Muhammad Ali of Gastroenterology Consultants of San Antonio
AGA urges members to petition Congress over FY17 funding bill: 4 thoughts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
